Results 301 to 310 of about 198,722 (342)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
New England Journal of Medicine, 2012 Keith T Flaherty +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
BRAF Heterogeneity in Melanoma
Current Treatment Options in Oncology, 2021In the era of molecular targeted therapy, the accurate detection of BRAF mutation in melanoma has become increasingly important. With the advances of molecular analyses and immunohistochemistry, the presence of BRAF mutational heterogeneity in melanoma has been widely recognized.
Takamichi Ito +5 more
openaire +2 more sources
Combined BRAF and MEK inhibition in BRAF-mutant NSCLC
The Lancet Oncology, 2016Refers to Planchard D, Besse B, Groen HJM, Souquet P, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial ...
Gareth, Rivalland, Paul, Mitchell
openaire +2 more sources
Critical Reviews in Oncology/Hematology, 2020
BRAF is a rare targetable mutation in non-small-cell lung cancer (NSCLC). Emerging evidence underlines that, rather than a single point mutation, BRAF genes present with a wide array of mutations, essentially in lung adenocarcinoma. Different BRAF mutations have divergent clinical and therapeutic implications, with a particular distinction between ...
Frisone D. +4 more
openaire +3 more sources
BRAF is a rare targetable mutation in non-small-cell lung cancer (NSCLC). Emerging evidence underlines that, rather than a single point mutation, BRAF genes present with a wide array of mutations, essentially in lung adenocarcinoma. Different BRAF mutations have divergent clinical and therapeutic implications, with a particular distinction between ...
Frisone D. +4 more
openaire +3 more sources
Radiosensibilisierung durch BRAF Inhibitoren
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2017ZusammenfassungHintergrundIn der letzten Zeit wurden in der Literatur vermehrt erhöhte Hauttoxizitäten während einer Kombinationstherapie mit BRAF Inhibitoren und Radiotherapie beschrieben.Material und MethodikWir berichten über sieben Melanompatienten in einem nicht resezierbaren Stadium III oder IV, die eine kombinierte Behandlung aus Bestrahlung und
Strobel, Sophia Boyoung +5 more
openaire +3 more sources
Radiosensitization by BRAF inhibitors
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2017BackgroundIncreased skin toxicity during combination therapy with a BRAF inhibitor and radiation therapy has recently been reported.Material and MethodsWe present seven melanoma patients with non‐resectable stage III or IV disease and concomitant treatment with a BRAF inhibitor and radiation therapy.ResultsIn all patients, combination therapy yielded a
Strobel, Sophia Boyoung +5 more
openaire +3 more sources
The Cancer Journal, 2011
Selective BRAF inhibitors have recently emerged as a new standard treatment for patients with metastatic melanoma harboring activating BRAF mutations. Inhibition of the MAP kinase pathway and initial evidence of antitumor effects are very reliably observed. However, many patients experience short-lived responses, whereas others are durable.
openaire +2 more sources
Selective BRAF inhibitors have recently emerged as a new standard treatment for patients with metastatic melanoma harboring activating BRAF mutations. Inhibition of the MAP kinase pathway and initial evidence of antitumor effects are very reliably observed. However, many patients experience short-lived responses, whereas others are durable.
openaire +2 more sources
BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors
Expert Opinion on Investigational Drugs, 2015Primary neuroepithelial brain tumors encompass a wide variety of glial and glioneuronal neoplasms. Malignant tumors, tumors located in surgically inaccessible locations (e.g., eloquent brain areas, deep structures, brain stem) and recurrent or progressive tumors pose considerable treatment challenges and are candidates for novel therapeutics based on ...
Matthias, Preusser +2 more
openaire +2 more sources
BRAF/MEK inhibition in melanoma patients with rare BRAF mutations.
Journal of Clinical Oncology, 20189542Background: BRAF/MEK inhibition is standard of care in patients (pts) with a BRAF V600E/K mutated melanoma. Efficacy data for pts with less frequent BRAF mutations are limited so far.
Hassel, Jessica Cecile +18 more
openaire +1 more source
BRAF and MEK inhibitors in BRAF-mutant melanoma
The Lancet Oncology, 2012Patients with melanoma and the Val600 BRAF mutation benefi t from combined inhibition of BRAF and MEK, according to a new study. Selective BRAF inhibitors such as dabrafenib and MEK inhibitors such as trametinib have individually been shown to increase progressionfree survival (PFS) and overall survival in Val600 BRAF-mutant melanoma.
openaire +1 more source